3 hours Vertex Pharmaceuticals (NASDAQ:VRTX) Receives “Overweight” Rating from Cantor Fitzgerald MarketBeat
Cantor Fitzgerald reiterated an “overweight” rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday.
Nasdaq 100 · Pharmaceuticals · Vertex (VRTX)